AMTD Digital Inc Reports 565.7% Revenue Growth in FY25
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy AARD?
Source: Benzinga
- Significant Revenue Growth: AMTD Digital Inc reported a staggering 565.7% year-over-year increase in FY25 revenue, reaching $136.1 million, which significantly enhances the company's financial performance and indicates strong market demand for its services.
- Stock Price Surge: Following the positive earnings report, AMTD Digital's shares jumped 24.4% to $2.18 in pre-market trading, reflecting investor optimism regarding the company's future growth potential and profitability.
- Positive Market Reaction: The robust financial results have garnered widespread attention in the market, potentially attracting more investors and further driving up the stock price while bolstering overall market confidence in the company.
- Strategic Implications: The revenue growth not only strengthens AMTD Digital's market position but also provides financial resources for future expansion and investments, enhancing its competitiveness in the digital finance sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AARD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AARD
Wall Street analysts forecast AARD stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.770
Low
18.00
Averages
33.00
High
50.00
Current: 3.770
Low
18.00
Averages
33.00
High
50.00
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aardvark Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Aardvark Therapeutics reported a Q4 GAAP EPS of -$0.81, beating expectations by $0.02, indicating improvements in financial management that may boost investor confidence.
- Significant Cash Reserves: As of December 31, 2025, Aardvark's cash and short-term investments totaled $110 million, a 49.9% increase from $73.7 million in 2024, providing a stronger financial foundation for future growth.
- Sufficient Operating Funds: Based on current operating plans, Aardvark believes its existing cash and short-term investments will fund operations into Q2 2027, demonstrating robustness in financial management and operational planning.
- Executive Appointment: Aardvark Therapeutics appointed Derrick C. Li as Chief Business Officer, aiming to enhance the company's business strategy and market expansion capabilities, potentially laying the groundwork for future growth.
See More
Aardvark Therapeutics Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Aardvark Therapeutics, Inc. for potential securities fraud or unlawful business practices, which could undermine investor confidence and lead to further stock price declines.
- Trial Suspension: On February 27, 2026, Aardvark announced a voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations found in a healthy volunteer study, potentially delaying product launch timelines and impacting future revenues.
- Stock Price Plunge: Following the trial suspension announcement, Aardvark's stock price plummeted by $7.02, or 56.2%, closing at $5.47 per share on March 2, 2026, reflecting extreme market pessimism regarding the company's outlook.
- Legal Implications: Pomerantz LLP, a prominent securities litigation firm, may initiate a class action lawsuit against Aardvark if the investigation confirms wrongdoing, which would severely impact the company's reputation and financial standing.
See More
AARDVARK THERAPEUTICS INC: B. RILEY LOWERS TARGET PRICE FROM $32 TO $8
- Target Price Adjustment: B. Riley has cut the target price for Aardvark Therapeutics from $32 to $8.
- Market Impact: This significant reduction reflects a reassessment of the company's market position and potential.
See More
Aardvark Therapeutics Reports Wider Losses in Q4 and FY2025
- Dismal Financial Results: Aardvark Therapeutics reported a net loss of $17.60 million in Q4 2025, translating to $0.81 per share, which is a significant increase from last year's loss of $8.78 million or $2.16 per share, indicating heightened financial pressures on the company.
- Annual Losses Widen: For the full year 2025, Aardvark's net loss expanded to $57.59 million, or $2.93 per share, compared to a loss of $20.59 million and $5.15 per share in the previous year, reflecting ongoing challenges in research and operational expenditures.
- Pipeline Update: Following unexpected reversible cardiac observations in a healthy volunteer trial, Aardvark has voluntarily paused the Phase 3 trials for ARD-101 and related trials for ARD-201, with further guidance expected in Q2 2026, highlighting the company's commitment to safety.
- Strong Cash Position: As of December 31, 2025, Aardvark had $110 million in cash and short-term investments, which is projected to fund operations into Q2 2027, demonstrating financial resilience despite ongoing R&D challenges.
See More
Investigation into Aardvark Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Aardvark Therapeutics, Inc. for potential securities fraud, focusing on whether the company and its executives engaged in unlawful business practices, which could lead to significant losses for investors.
- Trial Suspension: On February 27, 2026, Aardvark announced a voluntary pause of its Phase 3 Hunger Elimination or Reduction Objective (HERO) trial due to reversible cardiac observations at above-target therapeutic doses found during a healthy volunteer study, raising safety concerns.
- Stock Price Plunge: Following the trial suspension announcement, Aardvark's stock price fell by $7.02, or 56.2%, closing at $5.47 per share on March 2, 2026, indicating extreme market pessimism regarding the company's future prospects.
- Legal Implications: The investigation may lead to class action lawsuits against Aardvark, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking damages for affected investors, which could further impact the company's reputation and financial health.
See More
Pomerantz Investigates Aardvark Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Aardvark Therapeutics, Inc. for potential securities fraud or unlawful business practices, highlighting investor concerns regarding corporate governance and transparency.
- Trial Suspension: On February 27, 2026, Aardvark announced a voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations found during a healthy volunteer study, which could impact its future clinical development and market prospects.
- Stock Price Plunge: Following the trial suspension announcement, Aardvark's stock price fell by $7.02, or 56.2%, closing at $5.47 per share on March 2, 2026, reflecting extreme pessimism in the market regarding the company's future.
- Legal Implications: The investigation may lead to class action lawsuits against Aardvark, with investors seeking damages, further intensifying the company's legal and financial pressures and affecting its long-term strategic development.
See More
Aardvark Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Aardvark Therapeutics reported a Q4 GAAP EPS of -$0.81, beating expectations by $0.02, indicating improvements in financial management that may boost investor confidence.
- Significant Cash Reserves: As of December 31, 2025, Aardvark's cash and short-term investments totaled $110 million, a 49.9% increase from $73.7 million in 2024, providing a stronger financial foundation for future growth.
- Sufficient Operating Funds: Based on current operating plans, Aardvark believes its existing cash and short-term investments will fund operations into Q2 2027, demonstrating robustness in financial management and operational planning.
- Executive Appointment: Aardvark Therapeutics appointed Derrick C. Li as Chief Business Officer, aiming to enhance the company's business strategy and market expansion capabilities, potentially laying the groundwork for future growth.
See More
Aardvark Therapeutics Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Aardvark Therapeutics, Inc. for potential securities fraud or unlawful business practices, which could undermine investor confidence and lead to further stock price declines.
- Trial Suspension: On February 27, 2026, Aardvark announced a voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations found in a healthy volunteer study, potentially delaying product launch timelines and impacting future revenues.
- Stock Price Plunge: Following the trial suspension announcement, Aardvark's stock price plummeted by $7.02, or 56.2%, closing at $5.47 per share on March 2, 2026, reflecting extreme market pessimism regarding the company's outlook.
- Legal Implications: Pomerantz LLP, a prominent securities litigation firm, may initiate a class action lawsuit against Aardvark if the investigation confirms wrongdoing, which would severely impact the company's reputation and financial standing.
See More
AARDVARK THERAPEUTICS INC: B. RILEY LOWERS TARGET PRICE FROM $32 TO $8
- Target Price Adjustment: B. Riley has cut the target price for Aardvark Therapeutics from $32 to $8.
- Market Impact: This significant reduction reflects a reassessment of the company's market position and potential.
See More
Aardvark Therapeutics Reports Wider Losses in Q4 and FY2025
- Dismal Financial Results: Aardvark Therapeutics reported a net loss of $17.60 million in Q4 2025, translating to $0.81 per share, which is a significant increase from last year's loss of $8.78 million or $2.16 per share, indicating heightened financial pressures on the company.
- Annual Losses Widen: For the full year 2025, Aardvark's net loss expanded to $57.59 million, or $2.93 per share, compared to a loss of $20.59 million and $5.15 per share in the previous year, reflecting ongoing challenges in research and operational expenditures.
- Pipeline Update: Following unexpected reversible cardiac observations in a healthy volunteer trial, Aardvark has voluntarily paused the Phase 3 trials for ARD-101 and related trials for ARD-201, with further guidance expected in Q2 2026, highlighting the company's commitment to safety.
- Strong Cash Position: As of December 31, 2025, Aardvark had $110 million in cash and short-term investments, which is projected to fund operations into Q2 2027, demonstrating financial resilience despite ongoing R&D challenges.
See More
Investigation into Aardvark Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Aardvark Therapeutics, Inc. for potential securities fraud, focusing on whether the company and its executives engaged in unlawful business practices, which could lead to significant losses for investors.
- Trial Suspension: On February 27, 2026, Aardvark announced a voluntary pause of its Phase 3 Hunger Elimination or Reduction Objective (HERO) trial due to reversible cardiac observations at above-target therapeutic doses found during a healthy volunteer study, raising safety concerns.
- Stock Price Plunge: Following the trial suspension announcement, Aardvark's stock price fell by $7.02, or 56.2%, closing at $5.47 per share on March 2, 2026, indicating extreme market pessimism regarding the company's future prospects.
- Legal Implications: The investigation may lead to class action lawsuits against Aardvark, with Pomerantz LLP, a prominent securities litigation firm, potentially seeking damages for affected investors, which could further impact the company's reputation and financial health.
See More
Pomerantz Investigates Aardvark Therapeutics for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Aardvark Therapeutics, Inc. for potential securities fraud or unlawful business practices, highlighting investor concerns regarding corporate governance and transparency.
- Trial Suspension: On February 27, 2026, Aardvark announced a voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations found during a healthy volunteer study, which could impact its future clinical development and market prospects.
- Stock Price Plunge: Following the trial suspension announcement, Aardvark's stock price fell by $7.02, or 56.2%, closing at $5.47 per share on March 2, 2026, reflecting extreme pessimism in the market regarding the company's future.
- Legal Implications: The investigation may lead to class action lawsuits against Aardvark, with investors seeking damages, further intensifying the company's legal and financial pressures and affecting its long-term strategic development.
See More
